Shares of Keros Therapeutics, Inc. (KROS) have gained 3.7% over the past four weeks to close the last trading session at $11.44, but there could still be a solid upside left in the stock if short-term ...

Keros Therapeutics' stock has plummeted over 70% due to safety issues in its phase 2 PAH study, halting all trial arms. Learn more about KROS stock here.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In the presentation, titled “KROS 101: A Next Generation GITR agonist boosting anti-tumor T cell responses and reprogramming the tumor environment,” study authors demonstrated that KROS ...

During the last three months, 11 analysts shared their evaluations of Keros Therapeutics KROS, revealing diverse outlooks from bullish to bearish. The table below provides a snapshot of their ...

KROS opened at $11.08 on Friday. Keros Therapeutics has a fifty-two week low of $9.77 and a fifty-two week high of $73.00. The business has a 50-day moving average of $12.52 and a 200-day moving ...

Keros Therapeutics, Inc. (NASDAQ:KROS – Get Free Report) has received a consensus rating of “Moderate Buy” from the fourteen brokerages that are presently covering the stock, Marketbeat.com reports.